Spyre Therapeutics Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases

Reuters

10/24

<a href="https://laohu8.com/S/SYRE">Spyre Therapeutics</a> Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases

Spyre Therapeutics Inc. announced new scientific presentations at the upcoming American College of Rheumatology $(ACR)$ Convergence Congress. The company will present follow-up data from its Phase 1 study of SPY072, an investigational anti-TL1A monoclonal antibody being developed for rheumatic diseases. Interim results indicate that SPY072 is well tolerated and exhibits a pharmacokinetic profile that may support maintenance dosing every three or six months. In addition, new preclinical data will be presented showing that anti-TL1A antibody treatment demonstrated efficacy comparable to or exceeding etanercept in a rodent model of collagen-induced arthritis. These data provide further support for the ongoing SKYWAY Phase 2 study evaluating SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The posters will be available for viewing during the ACR Convergence Congress.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9550156-en) on October 24, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2577137245"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577137245\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577137245?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-24 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577137245","market":"fut","top_or_hot":-1,"title":"Spyre Therapeutics Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SYRE\">Spyre Therapeutics</a> Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Spyre <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced new scientific presentations at the upcoming American College of Rheumatology <a href=\"https://laohu8.com/S/ACR\">$(ACR)$</a> Convergence Congress. The company will present follow-up data from its Phase 1 study of SPY072, an investigational anti-TL1A monoclonal antibody being developed for rheumatic diseases. Interim results indicate that SPY072 is well tolerated and exhibits a pharmacokinetic profile that may support maintenance dosing every three or six months. In addition, new preclinical data will be presented showing that anti-TL1A antibody treatment demonstrated efficacy comparable to or exceeding etanercept in a rodent model of collagen-induced arthritis. These data provide further support for the ongoing SKYWAY Phase 2 study evaluating SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The posters will be available for viewing during the ACR Convergence Congress.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9550156-en) on October 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Spyre Therapeutics Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpyre Therapeutics Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-24 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SYRE\">Spyre Therapeutics</a> Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Spyre <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced new scientific presentations at the upcoming American College of Rheumatology <a href=\"https://laohu8.com/S/ACR\">$(ACR)$</a> Convergence Congress. The company will present follow-up data from its Phase 1 study of SPY072, an investigational anti-TL1A monoclonal antibody being developed for rheumatic diseases. Interim results indicate that SPY072 is well tolerated and exhibits a pharmacokinetic profile that may support maintenance dosing every three or six months. In addition, new preclinical data will be presented showing that anti-TL1A antibody treatment demonstrated efficacy comparable to or exceeding etanercept in a rodent model of collagen-induced arthritis. These data provide further support for the ongoing SKYWAY Phase 2 study evaluating SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The posters will be available for viewing during the ACR Convergence Congress.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9550156-en) on October 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDLmMH4j:1","article_id":"2577137245","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577137245","pubTimestamp":1761307226,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Spyre Therapeutics Inc. announced new scientific presentations at the upcoming American College of Rheumatology  Convergence Congress. The company will present follow-up data from its Phase 1 study of SPY072, an investigational anti-TL1A monoclonal antibody being developed for rheumatic diseases. Interim results indicate that SPY072 is well tolerated and exhibits a pharmacokinetic profile that may support maintenance dosing every three or six months. In addition, new preclinical data will be presented showing that anti-TL1A antibody treatment demonstrated efficacy comparable to or exceeding etanercept in a rodent model of collagen-induced arthritis. These data provide further support for the ongoing SKYWAY Phase 2 study evaluating SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The posters will be available for viewing during the ACR Convergence Congress.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelli","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SYRE":"SPYRE THERAPEUTICS INC"},"translate_title":"Spyre Therapeutics报告抗TL1A抗体SPY072治疗风湿性疾病的6个月1期阳性数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SYRE":0.9},"content_text":"Spyre Therapeutics Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases\n    \n\n        Spyre Therapeutics Inc. announced new scientific presentations at the upcoming American College of Rheumatology $(ACR)$ Convergence Congress. The company will present follow-up data from its Phase 1 study of SPY072, an investigational anti-TL1A monoclonal antibody being developed for rheumatic diseases. Interim results indicate that SPY072 is well tolerated and exhibits a pharmacokinetic profile that may support maintenance dosing every three or six months. In addition, new preclinical data will be presented showing that anti-TL1A antibody treatment demonstrated efficacy comparable to or exceeding etanercept in a rodent model of collagen-induced arthritis. These data provide further support for the ongoing SKYWAY Phase 2 study evaluating SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The posters will be available for viewing during the ACR Convergence Congress.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9550156-en) on October 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}